IceCure Medical

Executive Summary

IceCure Medical Ltd. is a commercial-stage medical technology company headquartered in Tel Aviv, Israel, focused on advancing minimally invasive cryoablation therapy for solid tumors. Its proprietary ProSense® system uses liquid nitrogen to deliver ultra-cold temperatures that freeze and destroy cancerous lesions in a procedure that can be performed on an outpatient basis. The platform has received regulatory clearances in key markets and is currently marketed for low-risk breast cancer, kidney, lung, and other solid tumor indications. With over $120 million raised to date, IceCure has established a commercial footprint and continues to build clinical evidence supporting the efficacy and safety of its technology, positioning it as a potential alternative to surgery in interventional oncology. IceCure's competitive advantage lies in the use of liquid nitrogen as the cooling agent—more efficient and cost-effective than argon-based systems—and the system's compact design that enables office-based procedures. The company is pursuing expansion into larger addressable markets, including benign breast tumors and additional oncology applications. While the cryoablation landscape includes established players, IceCure's differentiated approach and growing body of clinical data could support market share gains. Ongoing commercialization efforts and pipeline developments in target indications will be key to near-term value creation.

Upcoming Catalysts (preview)

• 2026FDA approval for breast cancer indication70% success
• H2 2026Pivotal trial results in lung or kidney tumors60% success
• 2026Strategic partnership or distribution deal in major market55% success